Novartis is taking a treatment for persistent hives into Phase III trials after a mid-stage trial showed that the medication, ligelizumab (QGE031), outperformed Xolair in patients with chronic spontaneous urticaria (CSU) patients whose symptoms are inadequately controlled by H1-antihistamines.
Johnson and Johnson said a combination therapy containing the company’s blockbuster cancer drug Imbruvica significantly improved survival in blood cancer patients, compared with drugs currently used as the standard of care.
A potential rival for Allergan Plc’s blockbuster Botox passed a late-stage study, putting drug developer Revance Therapeutics Inc. on course to file for U.S. marketing approval in 2019.
Roche’s Hemlibra provided sustained bleed control in the largest pivotal study to date of children with a form of hemophilia, the Swiss drugmaker said.
RedHill Biopharma’s combination antibiotic Talicia met the main goal of a late-stage study testing the drug in patients with a type of bacterial infection that affects the stomach and small intestine.
Noting that from 1998 to 2017 there were about 146 failed shots at developing drugs for Alzheimer’s disease, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a report on the state of the industry.
Dynavax Technologies shares fell more than 5 percent after the company reported that an asthma drug being jointly developed with AstraZeneca failed to meet endpoints in a mid-stage trial.
Alkermes Plc’s schizophrenia drug ALKS 3831 met the main goal of keeping in check a common side effect of antipsychotic medicines – weight gain – taking the company one step closer to a marketing approval for the experimental treatment.
Chicago-based AbbVie announced new data for Mavyret (glecaprevir/pibrentasvir), a pan-genotypic treatment for chronic HCV in treatment-naive patients with compensated cirrhosis.
Merck & Co.’s blockbuster drug Keytruda met the main goal of a late-stage trial testing the treatment in patients with cancers of the digestive tract.